According to filings with the U.S. Securities and Exchange Commission, Peak Bio is raising $100,000,000.00 in new funding. About Peak Bio: Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company’s lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California. Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer. Experienced management team with more than 50 plus years of industry experience in small molecules, antibodies, and antibody-drug-conjugates (ADC) drug development and has successfully forged companies that create best-in-class therapeutics during their tenures.

To learn more about Peak Bio, visit http://peak-bio.com/

Contact:
Stephen LaMond, Chief Executive Officer
925-463-4800

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.